feed,title,long_url,short_url
SeekingAlpha,Biogen misses top-line and bottom-line estimates; initiates FY24 outlook,https://seekingalpha.com/news/4065966,
SeekingAlpha,KalVista jumps as rare disease therapy hits main goal in Phase 3 trial,https://seekingalpha.com/news/4065965,
